Cargando…
Modulating inflammation to reduce atherosclerotic cardiovascular events: should colchicine be part of the therapeutic regimen?
Autores principales: | Jialal, Ishwarlal, Vikram, Naval |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8450546/ https://www.ncbi.nlm.nih.gov/pubmed/34533404 http://dx.doi.org/10.1177/17539447211042714 |
Ejemplares similares
-
Bempedoic Acid, an Inhibitor of Cholesterol Biosynthesis, Reduces Cardiovascular Events
por: Jialal, Ishwarlal, et al.
Publicado: (2023) -
Colchicine reduces atherosclerotic plaque vulnerability in rabbits
por: Roubille, François, et al.
Publicado: (2021) -
Comment on Lopes-Virella et al. Baseline Markers of Inflammation Are Associated With Progression to Macroalbuminuria in Type 1 Diabetic Subjects. Diabetes Care 2013;36:2317–2323
por: Jialal, Ishwarlal, et al.
Publicado: (2014) -
Role of C-Reactive Protein in Contributing to Increased Cardiovascular Risk in Metabolic Syndrome
por: Devaraj, Sridevi, et al.
Publicado: (2010) -
SAT-656 Both Neutrophil and Monocyte Ratios to High Density Lipoprotein Cholesterol Are Superior Biomarkers of Metabolic Syndrome
por: Ramakrishnan, Neeraj, et al.
Publicado: (2020)